What do we know about tailoring treatment with tenofovir?

被引：6

作者：

Calcagno, Andrea ^{[1
]}

Di Perri, Giovanni ^{[1
]}

Bonora, Stefano ^{[1
]}

机构：

[1] Univ Turin, Dept Med Sci, Infect Dis Unit, Turin, Italy

来源：

PHARMACOGENOMICS | 2016年 / 17卷 / 06期

关键词：

HIV; pharmacogenetics; pharmacokinetics; renal; tenofovir; toxicity; tubular; KIDNEY TUBULAR DYSFUNCTION; HIV-INFECTED PATIENTS; DISOPROXIL FUMARATE; RENAL-FUNCTION; ASSOCIATION; IMPAIRMENT; THERAPY; PLASMA; PHARMACOKINETICS; TRANSPORT;

D O I：

10.2217/pgs-2016-0003

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

页码：531 / 534

页数：4

共 24 条

[1] Common clinical conditions - age, low BMI, ritonavir use, mild renal impairment - affect tenofovir pharmacokinetics in a large cohort of HIV-infected women [J].

Baxi, Sanjiv M. ;

Greenblatt, Ruth M. ;

Bacchetti, Peter ;

Scherzer, Rebecca ;

Minkoff, Howard ;

Huang, Yong ;

Anastos, Kathryn ;

Cohen, Mardge ;

Gange, Stephen J. ;

Young, Mary ;

Shlipak, Michael G. ;

Gandhi, Monica .

AIDS, 2014, 28 (01) :59-66

[2] Tenofovir Plasma Concentrations According to Companion Drugs: a Cross-Sectional Study of HIV-Positive Patients with Normal Renal Function [J].

Calcagno, A. ;

de Requena, D. Gonzalez ;

Simiele, M. ;

D'Avolio, A. ;

Tettoni, M. C. ;

Salassa, B. ;

Orofino, G. ;

Bramato, C. ;

Libanore, V. ;

Motta, I. ;

Bigliano, P. ;

Orsucci, E. ;

Di Perri, G. ;

Bonora, S. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2013, 57 (04) :1840-1843

[3]

Calcagno A, 2015, AIDS

[4]

Calcagno A, 2015, PHARMACOGENOMICS J

[5] Systematic Review and Meta-analysis: Renal Safety of Tenofovir Disoproxil Fumarate in HIV-Infected Patients [J].

Cooper, Ryan D. ;

Wiebe, Natasha ;

Smith, Nathaniel ;

Keiser, Philip ;

Naicker, Saraladevi ;

Tonelli, Marcello .

CLINICAL INFECTIOUS DISEASES, 2010, 51 (05) :496-505

[6] Plasma and Intracellular Pharmacokinetics of Tenofovir Disoproxil Fumarate 300 mg Every 48 Hours vs 150 mg Once Daily in HIV-Infected Adults With Moderate Renal Function Impairment [J].

Cressey, Tim R. ;

Avihingsanon, Anchalee ;

Halue, Guttiga ;

Leenasirimakul, Prattana ;

Sukrakanchana, Pra-ornsuda ;

Tawon, Yardpiroon ;

Jaisieng, Nirattiya ;

Jourdain, Gonzague ;

Podany, Anthony T. ;

Fletcher, Courtney V. ;

Klinbuayaem, Virat ;

Bowonwatanuwong, Chureeratana .

CLINICAL INFECTIOUS DISEASES, 2015, 61 (04) :633-639

[7] A pharmacogenetic candidate gene study of tenofovir-associated Fanconi syndrome [J].

Dahlin, Amber ;

Wittwer, Matthias ;

de la Cruz, Melanie ;

Woo, Jonathan M. ;

Bam, Rujuta ;

Scharen-Guivel, Valeska ;

Flaherty, John ;

Ray, Adrian S. ;

Cihlar, Tomas ;

Gupta, Samir K. ;

Giacomini, Kathleen M. .

PHARMACOGENETICS AND GENOMICS, 2015, 25 (02) :82-92

[8] Long-term treatment with tenofovir: prevalence of kidney tubular dysfunction and its association with tenofovir plasma concentration [J].

Ezinga, Marieke ;

Wetzels, Jack F. M. ;

Bosch, Marjolein E. W. ;

van der Ven, Andre J. A. M. ;

Burger, David M. .

ANTIVIRAL THERAPY, 2014, 19 (08) :765-771

[9] Low Body Weight in Females Is a Risk Factor for Increased Tenofovir Exposure and Drug-Related Adverse Events [J].

Gervasoni, Cristina ;

Meraviglia, Paola ;

Landonio, Simona ;

Baldelli, Sara ;

Fucile, Serena ;

Castagnoli, Laura ;

Clementi, Emilio ;

Riva, Agostino ;

Galli, Massimo ;

Rizzardini, Giuliano ;

Cattaneo, Dario .

PLOS ONE, 2013, 8 (12)

[10] Should the dose of tenofovir be reduced to 200-250mg/day, when combined with protease inhibitors? [J].

Hill, Andrew ;

Khoo, Saye ;

Back, David ;

Pozniak, Anton ;

Boffito, Marta .

JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2014, 17 :64-65

← 1 2 3 →